A peer-reviewed scoping review published in The American Journal of Sports Medicine found that peptide supplements are being marketed to consumers faster than clinical evidence can support their safety and efficacy. The review, conducted by researchers including Dr. Jonathan Kremen, analyzed 565 studies on six widely sold peptides: BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu.
The analysis found that most available evidence for these compounds comes from animal or preclinical studies, while rigorous human clinical data remains largely lacking. Testing cited in the review also identified dangerous contaminants—including arsenic and lead—in some peptide products.
The findings come amid growing consumer interest in peptide supplements sold outside FDA-regulated channels. The reviewed peptides are not regulated or vetted by the FDA, leaving consumers without guarantees that products contain what their labels claim or are free from harmful contaminants.
What happened
The research team conducted a scoping review of 565 studies covering six peptides that have gained traction in supplement and wellness markets. The review, published in The American Journal of Sports Medicine, assessed the state of clinical evidence for each compound and compared it against marketing claims reaching consumers.
For all six peptides, the reviewers found that the volume and quality of human clinical evidence did not match the breadth of claims being made by sellers. Much of the existing research consists of animal studies or laboratory findings, which may not directly translate to demonstrated human safety or effectiveness.
The review also cited product testing that detected arsenic and lead in some peptide supplements, raising concerns about manufacturing standards and quality control in an unregulated market.
Why it matters
The review provides clinicians, consumers, and telehealth providers with an evidence-based reference point for evaluating peptide supplement claims. For consumers, the findings highlight a significant gap between what products promise and what science has actually demonstrated in human trials.
For clinicians and telehealth providers who may recommend peptides, the review underscores how limited the human safety and efficacy data currently is. Compounding pharmacies selling these compounds also face questions about quality standards, given the contamination findings cited in the study.
Affected groups include peptide consumers, clinicians recommending peptides, telehealth peptide providers, and compounding pharmacies selling BPC-157 and related compounds.
What to watch next
- Whether regulatory authorities respond to the evidence gap with new guidance or enforcement actions
- Whether additional peer-reviewed clinical research emerges for these six peptides
- How telehealth providers and compounding pharmacies adjust practices in response to the review’s findings
- Whether product testing and quality standards improve in the unregulated peptide supplement market
Sources
Medical Xpress / The American Journal of Sports Medicine
Industry information only. Not medical or legal advice.
